trending Market Intelligence /marketintelligence/en/news-insights/trending/Rb6u8sZPKYO0PC8rkomNXQ2 content esgSubNav
In This List

Cancer drug developer Aprea Therapeutics prices $85M Nasdaq IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cancer drug developer Aprea Therapeutics prices $85M Nasdaq IPO

Aprea Therapeutics Inc. priced its IPO of 5,666,667 common shares at $15 apiece.

The Boston-based biopharmaceutical company also granted underwriters a 30-day option to buy up to an additional 850,000 common shares.

Gross proceeds are expected to be about $85 million.

The company's common shares will begin trading on the Nasdaq Global Select Market on Oct. 3 under the APRE ticker symbol. The offering is expected to close Oct. 7.

J.P. Morgan, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the IPO.

Aprea Therapeutics develops therapies for blood cancers such as myelodysplastic syndromes and acute myeloid leukemia.